Compare IAUX & DMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IAUX | DMRA |
|---|---|---|
| Founded | 2020 | 2011 |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2021 | 2020 |
| Metric | IAUX | DMRA |
|---|---|---|
| Price | $1.54 | $24.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $1.50 | ★ $43.00 |
| AVG Volume (30 Days) | ★ 11.9M | 284.6K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.76 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $95,193,000.00 | N/A |
| Revenue This Year | $132.25 | N/A |
| Revenue Next Year | $89.76 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 89.12 | N/A |
| 52 Week Low | $0.49 | $16.50 |
| 52 Week High | $2.24 | $28.76 |
| Indicator | IAUX | DMRA |
|---|---|---|
| Relative Strength Index (RSI) | 47.48 | 47.61 |
| Support Level | $1.44 | $23.64 |
| Resistance Level | $1.95 | $28.00 |
| Average True Range (ATR) | 0.07 | 1.83 |
| MACD | 0.01 | -0.16 |
| Stochastic Oscillator | 42.05 | 50.60 |
i-80 Gold Corp is a well-financed gold and silver producer engaged in the exploration, development, and production of gold, silver, and poly-metallic deposits. The Company's principal assets include the Ruby Hill Mine, Lone Tree Mine, Granite Creek Mine, and McCoy-Cove Project.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.